Genprex (NASDAQ:GNPX) Shares Gap Down to $1.40

Genprex Inc (NASDAQ:GNPX)’s share price gapped down before the market opened on Friday . The stock had previously closed at $1.65, but opened at $1.40. Genprex shares last traded at $1.27, with a volume of 127,170 shares.

Separately, ValuEngine downgraded Genprex from a “buy” rating to a “hold” rating in a research report on Thursday.

The firm has a 50-day simple moving average of $0.37 and a two-hundred day simple moving average of $0.65. The company has a market cap of $36.42 million, a PE ratio of -1.67 and a beta of 1.28.

Genprex (NASDAQ:GNPX) last announced its quarterly earnings data on Thursday, November 14th. The company reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.07.

A hedge fund recently bought a new stake in Genprex stock. Citadel Advisors LLC acquired a new stake in Genprex Inc (NASDAQ:GNPX) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 31,529 shares of the company’s stock, valued at approximately $39,000. Citadel Advisors LLC owned 0.20% of Genprex as of its most recent SEC filing. Institutional investors and hedge funds own 10.38% of the company’s stock.

About Genprex (NASDAQ:GNPX)

Genprex, Inc operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells.

Featured Article: Percentage Decliners

Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.